À propos de la société
Ottobock SE & Co. KGaA develops, produces, and distributes medical technology products and components for the people with disabilities in the fields of prosthetics, orthotics, human mobility, and industrial exoskeletons in Europe, the Middle East, Africa, North and South America, and the Asia Pacific. The company is involved in identification, development, manufacturing, sales, and marketing of prosthetics, neuro-orthotics, and digital solutions; prostheses for the upper and lower extremities; mechanical prostheses and technologically sophisticated microprocessor-controlled; prosthetic knee joints and feet; arm and hand prostheses; and myoelectrical prostheses activities, as well as socket technologies, including liners, intelligent adaptors, and cosmetic components. It also provides fitting solutions for neurological indications; microprocessor-controlled orthotics, such as the C-Brace; and electrical muscle-activating stimulators, including exopulse suit and conventional orthotics; planning and equipping of patient care clinics; solutions for back, shoulder, neck, and wrist; customized orthopedic treatment and rehabilitation solutions; manual and power wheel chair; and standing aids and cushions, as well as care for amputees, including peripheral artery disease, traumatic limb loss, cancer, infections, congenital limb deficiencies, etc; and neurological etiologies, including stroke, multiple sclerosis, cerebral palsy/spinal cord injury, etc. In addition, the company leases out products, including wheelchairs and microprocessor-controlled knee joints. Ottobock SE & Co. was formerly known as Otto Bock HealthCare GmbH and changed its name to Ottobock SE & Co. KGaA in April 2018. The company was founded in 1919 and is based in Duderstadt, Germany. Ottobock SE & Co. KGaA operates as a subsidiary of Näder Upside 2 Vermögensverwaltungs GmbH.
- Secteur
- Healthcare
- Activité
- Medical Instruments & Supplies
- Place de cotation
- XETRA
Cotation non vérifiéeStatut du titre selon la dernière source reçue, pas une garantie de négociabilité.
Source des informations de marché · Oct 19, 2026